• INCLUSION CRITERIA

Participant is 18 years of age or older.

Participant has a diagnosis of sight-threatening, intermediate or posterior uveitis of at least three months duration prior to orginal enrollment, requiring treatment to control their intraocular inflammatory disease with at least 20 mg/day of prednisone (or equivalent) or any combination of two or more anti-inflammatory treatments for uveitis, including for example prednisone, cyclophosphamide, cyclosporine, azathioprine, mycophenolate mofetil, methotrexate, etc.

Participant exhibits intolerance to the indicated systemic medications required for their uveitis or, though their uveitis may be under control, wish to be taken off their present medications due to potential or actual unacceptable side effects.

Participant has visual acuity in at least one eye of 20/63 or better (ETDRS, logMAR less than 0.54).

Participant has normal renal or liver function or evidence of no worse than mild abnormalities as defined by the WHO/NEI criteria.

Participant is not currently pregnant or lactating.

Participant with reproductive potential and who is sexually active agrees to use acceptable birth control methods throughout the course of the study.

EXCLUSION CRITERIA

Participants under the age of 18 years.

Participants who had received previous treatment with an IL-2 directed monoclonal antibody or any other investigational agent that would interfere with the ability to evaluate the safety, efficacy or pharmacokinetics of daclizumab.

Participants with a history or diagnosis of Behcet's disease.

Participant has a significant active infection.

Participant has a history of cancer (other than a non-melanoma skin cancer) diagnosed within the past 5 years.

Participant is hypersensitive to fluorescein dye.